DACS
BCYC

Dymon Asia Capital (Singapore)’s Bicycle Therapeutics BCYC Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,000
Closed -$304K – 99
2024
Q2 		$304K Buy
+15,000
New +$339K 0.08% 84

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s BCYC Position: Q3 2024 in Review

Dymon Asia Capital (Singapore) sold out of Bicycle Therapeutics (BCYC) in Q3 2024, closing a stake of 15,000 shares — an estimated $304K sold.

Dymon Asia Capital (Singapore) first reported a position in BCYC in Q2 2024 and held it in 1 quarter. The position peaked at $304K in Q2 2024. 105 funds tracked by Wall St. Rank hold BCYC as of Q3 2024.

  • Dymon Asia Capital (Singapore) reported no remaining Bicycle Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Dymon Asia Capital (Singapore) sold 15,000 Bicycle Therapeutics shares in Q3 2024, an estimated $304K.
  • Dymon Asia Capital (Singapore) first reported a position in Bicycle Therapeutics in Q2 2024 and held it in 1 quarter.
  • Dymon Asia Capital (Singapore)'s Bicycle Therapeutics position peaked at $304K in Q2 2024.
  • 105 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2024.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q3 2024, filed 12 Nov 2024.